The metabolic disposition of DQ-2556 was studied in rats, rabbits, dogs, and monkeys after an intravenous administration of 20 mg of 14C-labeled drug per kg of body weight. The serum data were analyzed by the two-compartment open model. The mean half-lives for the drug in serum at excretion phase were 18.1, 54.4, 21.8, and 63.6 min in rats, rabbits, dogs, and monkeys, respectively. Many cephalosporins with 2-aminothiazol and methoxyimino groups in the substituent at the C-7 position, such as cefotaxime, ceftizoxime, and ceftriaxone, show excellent antibacterial activity against gram-positive and gram-negative microbes except Pseudomonas aeruginosa. Other cephalosporins with a 1-pyridinium group in the C-3 position, such as ceftazidime, are effective against P. aeruginosa. A new parenteral cephalosporin, DQ-2556, or (Fig. 1) , has both structural features in the same molecule (4) and has a broad antibacterial spectrum including activity against P. aeruginosa (5, 6). In this study, we describe the distribution, excretion, and metabolic fate of DQ-2556 Administration of the drug. All animals received a single bolus intravenous dose of [14C]DQ-2556 (20 mg/kg) over less than 5 s (for rats) or 1 min (for other animals). In the experiments with rats, sulfate of DQ-2556 was used after neutralization with sodium carbonate. In other experiments, the freeze-dried form was used. The drug was dissolved in distilled and sterilized water to a concentration of 1 ml/kg of body weight (for rats, rabbits, and monkeys) or 0.5 ml/kg (for dogs). The doses of radioactivity were 1.68 to 2.35 MBq/kg of body weight for rats, 1.59 MBq/kg for dogs, 1.57 MBq/kg for rabbits, and 1.73 to 2.80 MBq/kg for monkeys.
and has a broad antibacterial spectrum including activity against P. aeruginosa (5, 6) . In this study, we describe the distribution, excretion, and metabolic fate of DQ-2556 in rats, dogs, rabbits, and monkeys.
MATERIALS AND METHODS Chemicals. DQ-2556 was prepared by Daiichi Pharmaceutical Co., Ltd. (Tokyo) (4) and supplied as sulfate salt or the freeze-dried form, which contained equal amounts of DQ- or 1 min (for other animals). In the experiments with rats, sulfate of DQ-2556 was used after neutralization with sodium carbonate. In other experiments, the freeze-dried form was used. The drug was dissolved in distilled and sterilized water to a concentration of 1 ml/kg of body weight (for rats, rabbits, and monkeys) or 0.5 ml/kg (for dogs). The doses of radioactivity were 1.68 to 2.35 MBq/kg of body weight for rats, 1.59 MBq/kg for dogs, 1.57 MBq/kg for rabbits, and 1.73 to 2.80 MBq/kg for monkeys.
Collection of tissues and excreta. After drug administration, all animals were housed singly in stainless-steel metabolism cages which permitted the separate collection of urine and feces. The animals were fed ad libitum during the experimental periods.
Groups of four rats were killed by exsanguination by cutting the carotid artery under light ether anesthesia at various time intervals, and the blood was collected from each rat separately. Then tissues and gastrointestinal contents were removed. For four rats, urine was collected separately under dry ice cooling from each metabolism cage at various time intervals and feces were collected periodically from each metabolism cage. Bile was taken from four common bile duct-cannulated rats (10) Measurement of radioactivity. Radioactivity was measured in a liquid scintillation counter (models LSC-700 and 900; Aloka, Tokyo, Japan). All counts were corrected for quenching by the automatic external-standardization method (9) . Aliquots of serum, urine, bile, and homogenates of gastrointestinal contents (0.05 to 1.0 ml) were counted in 10 to 15 ml of scintillation cocktail (Aquasol-I1; NEN).
Whole blood (0.1 ml) on the filter papers and tissue samples (4 to 155 mg) was dried at room temperature and combusted in an automatic sample combustion system (models ASC-112 and 113; Aloka). The resultant 14C02 was trapped in 16 ml of scintillator containing 10 g of 2,5-diphenyloxazole, 0.5 g of 1,4-bis-(4-methyl-5-phenyl-2-oxazolyl)benzene, 1,000 ml of methanol, and 286 ml of monoethanolamine per liter of toluene, and the radioactivity was then determined. Feces were soaked in distilled water, lyophilized, and homogenized by grinding them in a motor. The radioactivity in the homogenized samples was measured by the same procedure as that for the tissue samples.
Autoradiography (ARG) . Rats were killed by anesthesia with ether at various time intervals and frozen by cooling with a dry ice-acetone mixture. The frozen animals were sliced into 30-pum-thick pieces by a freezing microtome (Cryomicrotome PMV-450; PMV Co., Stockholm, Sweden).
After lyophilization, the slices were exposed to X-ray film (Sakura H-type macroautoradiograph film; Konishiroku, Tokyo, Japan). A monkey was killed by anesthesia with ketamine hydrochloride and CO2 1 h after drug administration and then processed in the same way as the rats.
Serum protein binding. The extent of binding of DQ-2556 to serum protein was measured by ultracentrifugation (7) . A 0.2-ml aliquot of each serum sample was put into a sample tube and centrifuged at 200,000 x g at 4°C for 16 h. An 0.05-ml portion of the supernatant which was free from protein was taken, and the radioactivity in each sample was measured by the same procedure as was used for the serum. The concentration of DQ-2556 bound to protein was obtained by subtracting the concentration in the supernatant from the concentration in serum.
Erythrocyte binding. Aliquots of urine were analyzed by TLC, and the radioactive spots were scraped off into plastic vials. After standing for 30 min with 0.5 ml of 0.5 M NaOH, samples were neutralized with 0.5 M HCl, and the radioactivity was measured with a scintillation counter as described above.
Determination of concentrations of DQ-2556 in serum by HPLC. Three other monkeys were dosed intravenously with 20 mg of nonlabeled DQ-2556 per kg, and serum samples were collected at various time points as described above. The concentrations of DQ-2556 in serum were determined by HPLC (15) . To 0.5 ml of serum sample, 0.5 ml of 10% trichloroacetic acid containing 50 ,g of S-p-nitrobenzyl-Lcysteine as internal standard was added, and the sample was deproteinized. The separated supernatant was extracted with 7 ml of ether to remove trichloroacetic acid, and 50 ,ul of the remaining aqueous layer was injected for HPLC. HPLC analysis was performed with an SP8700 solvent delivery system (Spectra Physics, San Jose, Calif.) equipped with UV detector (Hitachi, Tokyo, Japan) and a stainlesssteel column (15 cm by 4.6 mm [inner diameter]) packed with 5-p,m octadecylsilica (TSK gel ODS 8OTM; Tosoh, Tokyo, Japan). The mobile phase was acetonitrile-0.02 M acetic acid (8:92, vol/vol), and the flow rate was 1.2 ml/min. The chromatograms were monitored by A306.
Purification and identification of unchanged drug in urine. After measurement of the radioactivity, the rat urine collected in the excretion experiment was pooled, applied to a column packed with polystyrene beads (2 cm [inner diameter] by 14 cm; Diaion HP-20 resin; Mitsubishi Kasei Co, Tokyo, Japan), and the column was washed with water. The adsorbed fractions were eluted with 20% acetonitrile. This eluate, which contained 79.8% of the radioactivity applied, was then separated by an HPLC (Waters 6000A; Nihon Waters Ltd., Tokyo, Japan) equipped with an octadecylsilica column (Cosmosil 10C18; 25 cm by 10 mm [inner diameter]; Nacalai Tesque Inc., Kyoto, Japan) using acetate buffer (water-acetonitrile-acetic acid-triethylamine, 300:30: 0.5:0.1). The chromatogram detected by A254 showed a major peak which contained most of the radioactivity, and this peak was collected. After concentration by evaporation, the fraction was further purified by HPLC with the same column using a mixture of diluted HCl (6 x 10-4 M)-acetonitrile (100:8) and then concentrated under reduced pressure. The purified fraction containing 47.8% of the radioactivity applied was crystallized as hydrochloride from a small volume of cold water, washed with aqueous ethanol, and dried under a vacuum. The proton nuclear magnetic resonance spectrum of the solution of metabolite in 2H20
was measured with a 500-MHz spectrometer (type GSX; JEOL Ltd., Tokyo, Japan), and tetramethylsilane was used as internal standard. The fast atom bombardment-mode mass spectrum was measured with a mass spectrometer (JMS-HX110; JEOL) with thioglycerol as matrix.
Pharmacokinetic analysis. Concentration in serum-versustime data were evaluated by both compartmental and noncompartmental pharmacokinetic methods MULTI, published by Yamaoka et al. (24) . The Akaike information criterion index calculated by this program was used as a model discrimination criterion. All data were weighted with the reciprocal of the concentration. Since the rats were different from time point to time point, interindividual variances of the parameters were not calculated.
RESULTS
Concentrations in whole blood and serum. Concentration of radioactivity in sera of rats receiving the dose of 20 mg/kg was 69.5 ,ug/ml at 5 min and declined in a biexponential fashion, with mean half-lives of 18.1 min and 10.6 h (Fig. 2) . In dogs, rabbits, and monkeys, levels in serum were 90.1, 65.8, and 120.9 ,ug/ml, respectively, at 5 min. Then, the levels declined in a similar way, with mean half-lives of 21.8 min and 8.45 h in dogs, 54.4 min and 41.7 h in rabbits, and 63.6 min and 28.1 h in monkey. Concentrations in serum were highest in monkeys, lowest in rats, and midlevel in dogs and rabbits at each time point. Concentrations in whole blood showed profiles similar to those of concentrations in serum in each species, but concentrations in serum were approximately 1.7 times higher than concentrations in whole blood at every time point. Concentrations of DQ-2556 in sera of other monkeys as determined by HPLC were comparable to those of radioactivity just after the administration of the drug (Fig. 3) . The concentration of DQ-2556 also declined biexponentially, and the half-lives were 9.3 ± 2.1 and 71.6 ± 2.6 min (mean ± standard error [SE]; n = 3) for each phase. The half-life of the second phase was comparable to that of the first phase in the radioactivity concentration-time profile. The concentration of DQ-2556 became significant lower than that of radioactivity 8 h or more after administration of the drug (P < 0.05, t test).
Pharmacokinetic analysis of serum concentration-versustime data yielded the parameter values shown in Table 1 . The V, was approximately 0.2 liter/kg and almost constant in all species except that it was a little higher in rabbits (P < 0.05 against dogs and monkeys, t test). For the area under the concentration-versus-time curve, values decreased in the same order as in concentrations in serum, whereas an inverse interspecies relation was observed for total body clearance.
Levels in tissue. Levels in tissue in rats are summarized in Table 2 . The radioactivity was quickly distributed to the tissues, and then the levels in tissue declined proportionately to levels in serum. The ratios of tissue/serum drug levels in the kidney, trachea, thyroid, skin, and lung at 5 min were 2.52, 0.89, 0.48, 0.46, and 0.44, respectively, and were larger than those for the other tissues ( Table 3 ). The ratios became higher with time in almost all tissues until 8 h after administration of the drug. ARG studies also showed excellent distribution of radioactivity into various tissues (data not shown). The ARGs of rats at 30 min after administration of the drug also revealed that l-evels of radioactivity in the kidney, trachea, skin, and lung were higher than those in other tissues. The ARGs of a monkey showed distribution similar to that observed in ARGs of rats. The amounts of radioactivity in gastrointestinal contents (mean + SE) were 5.1 ± 2.2, 7.8 + 0.8, and 2.4 + 1.5% of the dose at 2, 8, and 24 h after the dose, respectively. The elimination of radioactivity from the tissues was virtually completed by 8 h (Table 2) , and no accumulation of radioactivity in any tissues was observed.
Serum protein and erythrocyte binding. Serum protein binding is summarized in Table 4 . It was approximately 30% in rats and rabbits and approximately 20% in dogs and monkeys, whereas erythrocyte binding was very low in all species. Serum protein binding became higher with time in the same manner as seen in tissue levels.
Excretion. The mean excretion of radioactivity in each species is shown in Table 5 . Urine was the major excretory route in all species, and it accounted for 90.1 ± 2.6, 86.4 + 2.5, 94.4 + 4.7, and 90.0 ± 3.9% of the dose (mean ± SE) in rats, rabbits, dogs, and monkeys, respectively. A small portion of radioactivity, 3.1 ± 0.5% (mean ± SE) of the dose, was excreted into bile in rats. The concentrations of radioactivity in the bile were 40.1 ± 10.0, 60.9 + 13.1, 30.9 ± 6.4, 13.0 ± 3.9, and 5.1 ± 2.7 p,g/ml (mean ± SE) during periods of 0 to 1, 1 to 2, 2 to 4, 4 to 8, and 8 to 24 h after administration, respectively.
Metabolites. The urine was analyzed by TLC to detect urinary metabolite patterns, and typical ARGs of the TLC are shown in Fig. 4 . Since these ARGs were obtained by exposing the film long enough to detect very minor metabolites, the spots of metabolites or degradation products are rather exaggerated. Even in such conditions, a main spot having an Rf of 0.37 and identical to that of DQ-2556 was detected in chromatograms of urine from each animal species. The identification of this compound was further confirmed by comparison with an authentic sample of DQ-2556 by proton nuclear magnetic resonance and mass spectrometry after purification of the compound from rat urine by preparative HPLC. The nuclear magnetic resonance spectrum of this compound showed signals as follows (2H20, Metabolite composition in urine is summarized in Table 6 . The recoveries of unchanged drug in urine were 80.4 + 2.5, 49.1 + 11.0, 78.7 + 5.1, and 66.5% ± 6.4% of dose in rats, rabbits, dogs, and monkeys, respectively. The amounts of metabolites were very small in rat, dog, and monkey urine; however, substantial amounts of metabolites, mainly polar metabolites, were detected in rabbit urine. Although metabolites were detected in all species in the urine excreted in the later parts of the experiments, those metabolites did not make up a substantial percentage of the total because radioactivity excreted during these intervals was low.
DISCUSSION
Concentrations of radioactivity in serum samples from the four animal species declined biexponentially after administration of [14CJDQ-2556. Half-lives for the first phase were in the range of 18 to 64 min, and those for the second phase were very long. Most of the radioactivity was excreted within 2 to 4 h after administration of the drug in each species. Thus, it is known from the concentration-time profiles that the first phase represented mainly the excretion phase rather than the distribution phase. Decline in concentration in serum due to distribution might be so small and last so short a time that we could not get enough datum points to detect the distribution phase by computer calculation. This speculation was supported by the fact that V, values in these experiments were 0. (21), and also very near to the V,s of inulin in the rat (22) . These findings were consistent with the widely accepted concept that many cephalosporins are located only in extracellular water spaces (23) . Moreover, in the monkey, the concentration of unchanged drug in serum declined biexponentially and showed a phase with a much shorter half-life. The concentration in serum declined nearly monoexponentially after 1 h or more and became lower than the corresponding concentration of radioactivity as time passed (Fig. 3) . A similar profile was obtained in rats (data not shown). Thus, the second phase, in which the concentration of radioactivity in blood declined slowly, might represent the disposition of a small amount of metabolites which had higher levels of serum protein binding and a larger distribution volume than DQ-2556. Serum protein binding of DQ-2556 studied in in vitro experiments with serum and its component proteins at concentrations ranging from 1 to 100 ,ug/ml revealed no concentration dependency (data not shown). Thus, as time passed, the difference between the concentrations of radioactivity and DQ-2556 in serum became larger, the protein binding tissue/serum ratio became higher, and the proportion of DQ-2556 to urinary excretion became lower. The disposition of 14C-labeled latamoxef also showed a similar discrepancy between concentrations of unchanged drug and radioactivity in plasma in later parts of experiments (20) . This finding was explained by the production of unknown metabolites. The rabbit showed a somewhat larger Vc, longer half-life, and more metabolites than the other species. The mean residence time, the noncompartmental parameter, also seemed longer in the rabbit than in other species. These suggest that the rabbit might be different from the other species in metabolism of this drug. These differences may have some relation to the fact that rabbits were less susceptible than rats to nephrotoxicity with a high dose of DQ-2556 (11) .
Distribution of DQ-2556 into tissues was generally good, and high concentrations were achieved in the kidney, trachea, liver, thyroid, skin, and lung. As indicated in Tables 2  and 3 , DQ-2556 was distributed to almost all the tissues rapidly, and the concentration had already reached peak in each tissue by 5 min after administration of the drug. If the drug was not bound to proteins and could be distributed into the interstitial space of tissues, except those of the kidney and liver, concentration ratios for tissue/serum were estimated to be in the range of 0.13 to 0.38 when published physiological parameters were used (21 Fig. 4 . much higher than estimated values, although the mechanism of this phenomenon has not been identified. It is well known that in the kidney and liver, the ratios could become extremely large, because drugs are generally handled by special transport systems and distributed into the cells. DQ-2556 was distributed well, and the concentration ratio for tissue/ serum reached about 3. However, the ratio in liver, 0.36 at 30 min after administration of the drug, was not as high. Thus, DQ-2556 might be distributed into tissues by a mechanism other than diffusion into interstitial spaces, although it was not avidly transported into hepatic cells. Following intravenous administration of the drug, almost all parts of the radioactivity were excreted into urine in all species examined. Most of the radioactivity excreted into urine was attributed to the unchanged drug except in rabbits, in which a substantial amount of the radioactivity was excreted as polar metabolites. Thus, DQ-2556 was metabolized very little in rats, dogs, and monkeys and remained unchanged during disposition processes. The chemical structure of DQ-2556 is the same as that of cefotaxime except that the functional group at the C-3 position is changed from an acetoxy group to a quaternary ammonium group. However, metabolic stability of DQ-2556 was greater than that of cefotaxime, which has been reported to be deacetylated at the 3-acetoxymethyl group by rat liver enzymes (14) . In rabbits, DQ-2556 was metabolized into polar metabolites whose chemical properties have not been clarified.
Excretion of DQ-2556 proceeded mainly by the urinary route, and the rate in rats was almost equal to those of many other cephalosporin derivatives which, as reported by Brown et al. (3) , had quaternary ammonium in their 3' side chains. They reported that excretion of these compounds was not affected by administration of probenecid, a potent inhibitor of the secretion of anions at the proximal tubule of the kidney. Thus, these compounds, including DQ-2556, might be mainly excreted by glomerular filtration. Sokol (19) found in in vitro experiments that DQ-2556 at therapeutic concentrations had no detectable affinity for the carrier in renal drug secretion systems. Although biliary excretion of DQ-2556 was very low (3.1% of the dose within 24 h), the biliary concentration of radioactivity was equal to the concentration in serum within 1 h after administration of the drug, and after that, it became 6 to 30 times higher than the concentration in serum. Thus, DQ-2556 could be categorized in class B of Klaassen and Watkins's classification (12) and might be secreted by some active transport systems. As a whole, however, biliary excretion did not play a major role in the disposition of this compound.
Protein binding is one of the important factors which affect distribution of drugs in the body. Since only the free fraction of a drug of low molecular weight in plasma can be equilibrated with that in the extracellular fluid space (16) , the low affinity of DQ-2556 for serum protein is advantageous for attaining high concentration ratios for tissue/serum. A group of new cephalosporins such as ceftazidime (1, 17) , cefepime (2) , and cefpirome (13) also have a quaternary ammonium group at the C-3 position, and their protein binding ratios are 20% or less. Ceftazidime and cefepime were reported to be distributed well in the lung and other tissues (8) . These cephalosporins, including DQ-2556, might compose a group of antibiotics with new pharmacokinetic properties.
